Quetiapine (QTP) is a dibenzothiazepine derivative used clinically as a second-generation atypical antipsychotic, ranking among the most frequently prescribed agents in its class. Beyond its approved indications for schizophrenia and bipolar disorder, it is widely utilized off-label for other psychiatric conditions. The antidepressant and mood-stabilizing effects of quetiapine are closely correlated with the plasma concentrations of both the parent drug and its primary circulating metabolite, norquetiapine. Overdose can result in coma, respiratory insufficiency, and severe hypotension. Over the past two decades, the exponential growth in clinical use has coincided with a surge in acute poisoning cases, some of which have proven fatal. Consequently, implementing Therapeutic Drug Monitoring (TDM) for quetiapine holds significant clinical value in mitigating dose-dependent toxicity, optimizing pharmacotherapy, and elucidating inter-individual variability in drug response.

AccuSift provides high-performance competitive antibody pairs for quetiapine detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 0.1 ng/mL